Pathogenesis of chronic inflammatory bowel diseases;Pathogenese chronisch entzündlicher darmerkrankungen

Praxis

Volumn 95, Issue 50, 2006, Pages 1965-1973

  Kreisel, W ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Crohn's disease; Defensins; Innate immune system; Intestinal bacteria, genetic predisposition; NOD2; Toll like receptors; Ulcerative colitis

Indexed keywords

ANTIINFECTIVE AGENT; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CORTICOSTEROID; CYTOKINE; DEFENSIN; INTERLEUKIN DERIVATIVE; PROBIOTIC AGENT; TOLL LIKE RECEPTOR;

BACTERIAL INFECTION; BACTERIUM; COMPARATIVE STUDY; CROHN DISEASE; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOLOGY; INTESTINE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MUTATION; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW; RISK FACTOR; SECRETION; T LYMPHOCYTE; ULCERATIVE COLITIS;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; COLITIS, ULCERATIVE; CROHN DISEASE; CYTOKINES; DEFENSINS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKINS; INTESTINES; MUTATION; NOD2 SIGNALING ADAPTOR PROTEIN; PROBIOTICS; RISK FACTORS; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 33845929202     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/1661-8157.95.50.1965     Document Type: Review

References (76)

1. Podolsky D.K.: Inflammatory bowel disease. N Engl J Med 347: 417-429, 2002.
2. Rogler G.: Update in inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol 20: 311-317, 2004.
3. Herrlinger K., Stange E.F.: Chronisch entzündliche Darmerkrankungen. Internist 44: 1151-1173, 2003.
4. Bamias G, Nyce MR, De la Rue S, Cominelli F. New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med; 143: 895-904. 2005 (Pubitemid 46202223)
5. Orholm M., Munkholm P., Langholz E., Nielsen O.H., Sørensen T.I.A., Binder V.: Familial occurrence of inflammatory bowel disease. N Engl J Med 324: 84-88, 1991.
6. Ahmad T., Tamboli C.P., Jewell D., Colombel J.F.: Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology 126: 1533-1549, 2004. (Pubitemid 38649871)
7. Newman B., Siminovitch K.A.: Recent advances in the genetics of inflammatory bowel disease. Curr Opin Gastroenterol 21: 401-407, 2005. (Pubitemid 40961164)
8. Hugot J.P., Laurent-Ouig P., Gower-Rousseau C. et al.: Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 379: 821-823, 1996. (Pubitemid 26067722)
9. Bonen D.K., Cho J.H.: The genetics of inflammatory bowel disease. Gastroenterology 124: 521-536, 2003. (Pubitemid 36169267)
10. Cashman K.D., Shanahan F.: Is nutrition an aetiological factor for inflammatory bowel disease? European Journal of Gastroenterology &Hepatology 15: 607-613, 2003. (Pubitemid 36688223)
11. Lindberg E., Tysk C., Andersson K., Jarnerot G.: Smoking and inflammatory bowel disease: a case control study. Gut 29: 352-357, 1988. (Pubitemid 18082152)
12. Andersson R.E., Olaison G., Tysk C., Ekbom A.: Appendectomy and protection against ulcerative colitis. N Engl J Med 344: 808-814, 2001. (Pubitemid 32222158)
13. Swidsinski A., Ladhoff A., Pernthaler A., et al.: Mucosal flora in inflammatory bowel disease. Gastroenterology 122: 44-54, 2002. (Pubitemid 34049193)
14. Tamboli C.P., Neut C., Desreumaux P., Colombel J.F.: Dysbiosis in inflammatory bowel disease. Gut 53: 1-4, 2004. (Pubitemid 38082999)
15. Ryan P., Bennett M.W., Aarons S., Lee G., Collins J.K., O'Sullivan G.C.: PCR detection of Mycobacterium paratuberculosis in Crohn's disease granulomas isolated by laser capture microdissection. Gut 51: 665-670, 2002. (Pubitemid 35216853)
16. Liu Y., van Kruiningen H.J., West A.B., Cartun R.W., Cortot A., Colombel J.F.: Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology 108: 1396-1404, 1995.
17. Chadwick N., Bruce I.J., Schepelmann S., Pounder R.E., Wakefield A.J.: Measles virus DNA is not detected in inflammatory bowel disease using hybrid capture and reverse transcriptase followed by polymerase chain reaction. J Med Virol 55: 305-311, 1998. (Pubitemid 28302486)
18. Shanahan F., O'Mahony J.: The mycobacteria story in Crohn's disease. Am J Gastroenterol 100: 1537-1538, 2005. (Pubitemid 41032359)
19. Guarner F.: The intestinal flora in inflammatory bowel disease: normal or abnormal? Curr Opin Gastroenterol 21: 414-418, 2005.
20. Hugot J.P., Alberti C., Berrebi D., Bingen E., Cézard J.P.: Crohn's disease: the cold chain hypothesis. Lancet 362: 2012-2015, 2003. (Pubitemid 37548429)
21. Korzenik J.R.: Past and current theories of etiology of IBD. Toothpaste, worms, and refrigerators. J Clin Gastroenterol 39: S59-S65, 2005.
22. Gibson P.R.: Increased gut permeability in Crohn's disease: is TNF the link? Gut 53: 1724-1725, 2004.
23. Seibold F.: ASCA: genetic marker, predictor of disease, or marker of a response to an environmental antigen? Gut 54: 1212-1213, 2005.
24. Söderholm J.D., Streutker C., Yang P.C., Paterson C., Singh P.K., McKay D.M., Sherman P.M., Croitoru K., Perdue M.H.: Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumour necrosis factor a. Gut 53: 1817-1824, 2004. (Pubitemid 39556903)
25. Meddings J.B.: Intestinal permeability in Crohn's disease. Aliment Pharmacol Ther 11 (Suppl. 3): 47-56, 1997.
26. Maunder R.G.: Evidence that stress contribute to inlammatory bowel disease: Evaluation, synthesis, and future directions. Inflamm Bowel Dis 11: 600-808, 2005.
27. Mawdsley J.E., Rampton D.S.: Psychological stress in IBD: New insights into pathogenic and therapeutic implications. Gut 54: 1481-1491, 2005. (Pubitemid 41375207)
28. Bouma G., Strober W.: The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3: 521-533, 2003. (Pubitemid 37328672)
29. Van Deventer S.J.H. Tumour necrosis factor and Crohn's disease. Gut 40: 443-448, 1997. (Pubitemid 27204920)
30. Van Assche G., Rutgeerts P.: Antiadhesion molecule therapy in inflammatory bowel disease. Inflamm Bowel Dis 8: 291-300, 2002. (Pubitemid 34784983)
31. Van Deventer S.J.H.: Anti-tumour necrosis factor therapy in Crohn's disease: where are we now? Gut 51: 362-363, 2002.
32. Elson C.O.: Genes, microbes, and T-cells - new therapeutic targets in Crohn's disease. New Engl J Med 346: 614-615, 2002.
33. Sandborn W.J., Targan S.R.: Biological therapy of inflammatory bowel disease. Gastroenterology 118: 1592-1608, 2002. (Pubitemid 34533555)
34. Eksteen B., Walker L.S.K., Adams D.H.: Immune regulation and colitis: suppression of acute inflammation allows the development of chronic inflammatory bowel disease. Gut 54: 4-6, 2005. (Pubitemid 40007209)
35. Suenart P., Bulteel V., Vermeire S., Noman M., Van Assche G., Rutgeerts P.: Hyperresponsiveness of the mucosal barrier in Crohn's disease is not tumor necrosis factor-dependent. Inflamm Bowel Dis 11: 667-673, 2005. (Pubitemid 40961081)
36. Gordon J.N., Di Sabatino A., MacDonald T.T.: The pathophysiologic rationale for biological therapies in inflammatory bowel disease. Curr Opin Gastroenterol 21: 431-437, 2005. (Pubitemid 40961169)
37. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cézard J.P., Belaiche J., Almer S., Tysk C., O'Morain C.O., Gassul M., Binder V., Finkel Y., Cortot A., Modigliani R., Laurent-Puig P., Gower-Rousseau C., Macry J., Colombel J.F., Sahbatou M., Thomas G.: Association of NOD2 leucinerich repeat variants with susceptibility to Crohn's disease. Nature 411: 599-603, 2001. (Pubitemid 32531408)
38. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., Britton H., Moran T., Karaliuskas R., Duerr R.H., Achkar J.P., Brant S.R., Bayless T.M., Kirschner B.S., Hanauer S.B., Nuñez G., Cho J.H.: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411: 537-539, 2001.
39. Janeway Jr. C.A., Medzhitov R.: Innate immune recognition. Annu Rev Immunol 20: 197-216, 2002. (Pubitemid 34293424)
40. Cario E.: Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 54: 1182-1193, 2005.
41. Neish S.A.: Molecular aspects of intestinal epithelial cell-bacterial interactions that determine the development of intestinal inflammation. Inflamm Bowel Dis 10: 159-168, 2004.
42. Dabbagh K., Lewis D.B.: Toll-like receptors and T-helper-1/-helper-2 responses. Curr Opin Infect Dis 16: 199-204, 2003.
43. Medzhitov R.: Toll-like receptors and innate immunity. Nature Rev Immunol 1: 136-145, 2001. Da ist ein Bild drin.
44. Neurath M.F., Finotto S., Glimcher L.H.: The role of Th1/Th2 polarization in mucosal immunity.Nat Med 8: 567-573, 2002. (Pubitemid 34633433)
45. Jump R.L., Levine A.D.: Mechanisms of natural tolerance in the intestine. Implications for inflammatory bowel disease. Inflamm Bowel Dis 10: 462-478, 2004. (Pubitemid 39029194)
46. Mueller T., Podolsky D.K.: Nucleotide-binding-oligomerisation domain proteins and toll-like receptors: sensors of the inflammatory bowel diseases' microbial environment. Curr Opin Gastroenterol 21: 419-425, 2005. (Pubitemid 40961167)
47. Ouelette A.J.: Defensin-mediated innate immunity in the small intestine. Best Practice & Research Clinical Gastroenterology 18: 405-419, 2004.
48. Eckmann L.: Defence molecules in intestinal innate immunity against bacterial infections. Curr Opin Gastroenterol 21: 147-151, 2005.
49. Murillo L.S., Morré S.A., Peña A.S.: Role of the CARD15 gene in the pathogenesis of Crohn Disease: Phenotypic classification and prognostic implications. Scand J Gastroenterol 38: 1235-1240, 2003.
50. Cummings J.R.F., Jewell D.P.: Clinical implications of inflammatory bowel disease genetics on phenotype. Inflamm Bowel Dis 11: 56-61, 2005.
51. Girardin S.E., Boneca I.G., Carneiro L.A.M., Antignac A., Jéhanno M., Viala J., Tedin U., Taha M.K., Labigne A., Zähringer U., Coyle A.J., DiStefano P.S., Bertin J., Sansonetti P.J., Philpott D.J.: Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 300: 1584-1587, 2003. (Pubitemid 36682892)
52. Zouali H., Lesage S., Merlin F., Cézard J.P. and the EPWG-IBD group, Colombel J.F. and the EPIMAD group, Belaiche J. and the GETAID group, Almer S., Tysk C., O'Morain C., Gassull M., Christensen S., Finkel Y., Modigliani R., Gower-Rousseau C., Macry J., Chamaillard M., Thomas G., Hugot J.P.: CARD4/NOD1 is not involved in inflammatory bowel disease. Gut 52: 71-74, 2003.
53. Bonen D.K., Ohura Y., Nicolae D.L., Inohara N., Saab L., Tanabe T., Chen F.F., Foster S.J., Duerr R.H., Brant S.R., Cho J.H., Nuñez G.: Crohn's disease-associated NOD2 variants share a signalling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 124: 140-146, 2003. (Pubitemid 36055347)
54. Hisamatsu T., Suzuki M., Reinecker H.C., Nadeau W.J., McCormick B.A., Podolsky D.K.: CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 124: 993-1000, 2003. (Pubitemid 36389802)
55. Rosenstiel P., Fantini M., Bräutigam K., Kühbacher T., Waetzig G.H., Seegert D., Schreiber S.: TNF-α and IFN-&β regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells, Gastroenterology 124: 1001-1009, 2003. (Pubitemid 36389803)
56. Inohara N., Ogura Y., Fontalba A., Gutierrez O., Pons F., Crespo J., Fukase K., Inamura S., Kusumoto S., Hshimoto M., Foster S.J., Moran A.P., Fernandez-Luna J.L., Nuñez G.: Host recognition of bacterial muramyl dipeptide mediated through NOD2. J Biol Chem 278: 5509-5512, 2003. (Pubitemid 36800790)
57. Giradin S.E., Travassos L.H., Hervé M., Blanot D., Boneca I.G., Philpott D.J., SAnsonetti P.J., Mengin-Lecreulx D.: Peptidoglycan molecular requirements allowing detection by NOD1 and NOD2. J Biol Chem 278: 41702-41708, 2003. (Pubitemid 37310428)
58. Van Heel D.A., Ghosh S., Butler M., Hunt K.A., Lundberg A.M.C., Ahmad T., MocGovern D.P.B., Onnie C., Negoro K., Goldthorpe S., Foxwell B.M.J., Mathew C.G., Forbes A., Jewell D.P., Playford R.J.: Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet 365: 1794-1796, 2005.
59. Meinzer U., Hugot J.P.: Nod2 and Crohn's disease: many connected highways. Lancet 365: 1752-1753, 2005.
60. Fellermann K., Wehkamp J., Herrlinger K.R., Stange E.F.: Crohn's disease: a defensin deficiency syndrome? European Journal of Gastroenterology & Hepatology 15: 627-634, 2003. (Pubitemid 36688226)
61. Wehkamp J., Harder J., Weichenthal M., Mueller O., Herrlinger K.R., Fellermann K., Schroeder J.M., Stange E.F.: Inducible and constitutive β-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 9: 215-223, 2003.
62. Grimm M.C., Pavli P.: NOD2 mutations and Crohn's disease: are Paneth cells and their antimicrobial peptides the link? Gut 53: 1558-1560, 2004. (Pubitemid 39434093)
63. Wehkamp J., Harder J., Weichenthal M., Schwab M., Schäffeler E., Schlee M., Herrlinger K.R., Stallmach A., Noack F., Fritz P., Schröder J.M., Bevins C.L., Fellermann K., Stange E.F.: NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal a-defensin expression. Gut 53: 1658-1664, 2004. (Pubitemid 39434112)
64. Wehkamp J., Fellermann K., Stange E.F.: Human defensins in Crohn's disease. A molecular link to mucosal barrier dysfunction. Chem Immunol Allergy 86; 42-54, 2005. (Pubitemid 40904997)
65. Schwab M., Schaeffeler E., Marx C., Fromm M.F., Kaskas B., Metzler J., Stange E., Herfarth H., Schoelmerich J., Gregor M., Walker S., Cascorbi I., Roots I., Brinkmann U., Zanger U.M., Eichelbaum M.: Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 124: 26-33, 2003. (Pubitemid 36055335)
66. Franchimont D., Vermeire S., El Housni H., Pierik M., Van Steen K., Gustot T., Quertinmont E., Abramovicz M., Van Gossum A., Devière J., Rutgeerts P.: Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 53: 987-992, 2004. (Pubitemid 38824157)
67. Török H.P., Glas J., Tonenchi L., Lohse P., Müller-Myhsol B., Limbersky O., Neugebauer C., Schnitzler F., Seiderer J., Tillack C., Brand S., Brünnler G., Jagiello P., Epplen J.T., Griga T., Klein W., Schiemann U., Folwaczny M., Ochsenkühn T., Folwaczny C.: Polymorphisms in the DLG5 and OCTN cation transporter genes in Crohn's disease. Gut 54: 1421-1427, 2005. (Pubitemid 41375199)
68. Obermeier F., Strauch U.G., Dunger N., Grunwald N., Rath H.C., Herfarth H., Schölmerich J., Falk W.: In vivo CpG DNA/toll-like receptor 9 interaction induces regulatory properties in CD4+D62L+ T cells which prevent intestinal inflammation in the SCID transfer model of colitis. Gut 54: 1428-1436, 2005. (Pubitemid 41375200)
69. Linderson Y., Bresso F., Buentke E., Petterson S., D'Amato M.: Functional interaction of CARD15/NOD2 and Crohn's disease-associated TNFα polymorphisms. Int J Colorectal Dis 20: 3053-311, 2005.
70. Oostenbrug L.E., Drenth J.P.H., de Jong D.J., Nolte I.N., Oosterom E., van Dullemen H.M., van der Linde K., te Meerman G.J., van der Steege G., Kleibeuker J.H., Jansen P.L.M.: Association between toll-like receptor 4 and inflammatory bowel disease Inflamm Bowel Dis 11: 567-575, 2005. (Pubitemid 40826344)
71. Noble C.L., Nimmo E.R., Drummond H., Smith L., Arnott I.D.R., Satsangi J.: DLG5 variants do not influence susceptibility to inflammatory bowel disease in the Scottish population. Gut 54: 1416-1420, 2005. (Pubitemid 41375198)
72. Brand S., Staudinger T., Schnitzler F., Pfennig S., Hofbauer K., Dambacher J., Seiderer J., Tillack C., Konrad A., Crispin A., Göke B., Lohse P., Ochsenkühn T.: The role of toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis 11: 645-652, 2005. (Pubitemid 40965520)
73. Singh B., Read S., Asseman C. et al.: Control of intestinal inflammation by regulatory T cells. Immunol Rev 182: 190-200, 2001. (Pubitemid 33070218)
74. Maul J., Loddenkemper C., Mundt P., Berg E., Giese T., Stallmach A., Zeitz M., Duchmann R.: Peripheral and intestinal regulatory CD4+CD25high T cells in inflammatory bowel disease Gastroenterology 128: 1868-1878, 2005. (Pubitemid 40824698)
75. Watanabe T., Yamori M., Kita T., Chiba T., Wakatsuki Y.: CD4+CD25+T cells regulate colonic localization of CD4 T cells reactive to a microbial antigen. Inflamm Bowel Dis 11: 541-550, 2005. (Pubitemid 40826341)
76. Sartor R.B.: Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126: 1620-1633, 2004.